Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 33

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
, 2024. Early adoption is permitted. 

NOTE 3: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets are comprised
of the following:

SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS 

    March 31, 2025  
    December 31, 2024 
  
    Prepaid insurance 
    $295,093  
    $506,489 
  
    Prepaid research and development 
     400,179  
     150,000 
  
    Other prepaid expenses 
     374,638  
     175,088 
  
    Total prepaid expenses and other current assets 
    $1,069,910  
    $831,577 
  
    Prepaid expenses and other current assets 
    $1,069,910  
    $831,577 

NOTE 4: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are
comprised of the following:

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES 

    March 31, 2025  
    December 31, 2024 
  
    Accounts payable 
    $1,311,095  
    $870,229 
  
    Accrued employee costs 
     83,466  
     1,371,498 
  
    Accrued professional fees 
     69,959  
     72,054 
  
    Accrued research and development 
     898,067  
     860,958 
  
    Accrued board fees 
     117,750  
     117,750 
  
    Other accrued expenses 
     72,042  
     17,228 
  
    Total accounts payable and other current liabilities 
    $2,552,379  
    $3,309,717 

NOTE 5: STOCK-BASED COMPENSATION

The Company has an equity incentive plan for grants
to employees, officers, consultants, directors, and other service providers that was approved in 2021 (the “2021 Plan”). The
2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units,
unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s
board to change the type,